VivoSeq
Oncology

MALT Lymphoma

15

Pipeline Programs↗

9

Active Trials↗

10

Companies Involved↗

MALT lymphoma is an emerging landscape with 15 programs across 10 companies. The most active players are Beijing InnoCare Pharma Tech Co., Ltd., Karuna Therapeutics, Inc., a Bristol Myers Squibb company, Dexcel Pharma Technologies Ltd.. 2 therapies are approved with 2 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

45/100

Pipeline Velocity

15/100

Mech. Concentration

14/100

Completion Rate

88/100

Attrition Rate

6/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

B

Beijing InnoCare Pharma Tech Co., Ltd.

1 program

Phase 2K

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

1 program

Phase 2D

Dexcel Pharma Technologies Ltd.

1 program

Phase 2AbbVie logo

AbbVie

1 program

Phase 2Biogen logo

Biogen

1 program

Phase 2Akero Therapeutics logo

Akero Therapeutics

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Modality Breakdown

95%

Small molecule

18 of 19 classified programs — the dominant modality here.

5%ALL OTHERSMonoclonal antibody15%

Small molecule leads; the ring shows all 19 classified programs, each share of the total. Modality classified for 100% of 19 pipeline programs.

Analysis

Trial Status

18

clinical trials

Completed7 · 39%
Active, not recruiting4 · 22%
Not yet recruiting3 · 17%
Recruiting2 · 11%
Unknown status1 · 6%
Terminated1 · 6%

Clinical Trials

Trial Activity

18 trials

Orelabrutinib in the Treatment of HP-positive Gastric MALT Lymphoma
Recruiting·FFudan University·Phase 2·NCT06228963·160 enrolled
RCT on Intralesional Rituximab Injection Versus ISRT in Ocular Adnexal MALT Lymphoma
Recruiting·ZZhongshan Ophthalmic Center, Sun Yat-sen University·N/A·NCT06190301·108 enrolled
Phase II Study of Chlorambucil and Subcutaneous Rituximab in Patients With Extranodal MALT Lymphoma
Active, not recruiting·IInternational Extranodal Lymphoma Study Group (IELSG)·Phase 2·NCT01808599·112 enrolled
Orelabrutinib Followed by Response-adapted Ultra-low Dose 4Gy Radiation as First-line Treatment of MALT Lymphoma
Active, not recruiting·FFudan University·Phase 2·NCT06583837·50 enrolled
Ultra Low-Dose Radiation Therapy in Treating Patients With Stage I-IV Stomach MALT Lymphoma
Active, not recruiting·MM.D. Anderson Cancer Center·Phase 1·NCT03680586·25 enrolled
Orelabrutinib Plus Low-Dose Radiotherapy Or Rituximab For Ocular Adnexal MALT Lymphoma
Active, not recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 2·NCT07247383·39 enrolled
RCT of Intralesional Rituximab Injection Versus Involved Site Radiation Therapy in Ocular Adnexal MALT Lymphoma
Not yet recruiting·ZZhongshan Ophthalmic Center, Sun Yat-sen University·N/A·NCT06064344·108 enrolled
Prospective Study of Frontline Antibiotics Therapy in the Treatment of Early-stage HP-negative Gastric MALT Lymphoma
Not yet recruiting·NNational Taiwan University Hospital·Phase 2·NCT07144657·40 enrolled
Molecular and Cellular Characterization of MALT Lymphoma Across Anatomical Sites: Integrative Transcriptomic and Epigenetic Approaches
Not yet recruiting·IInternational Extranodal Lymphoma Study Group (IELSG)·N/A·NCT07376330·400 enrolled
R-CVP for the Treatment of Non-conjunctival Ocular Adnexal MALT Lymphoma (OAML)
Completed·KKonkuk University Medical Center·Phase 2·NCT01427114·33 enrolled
Prognostic Study of Gastric MALT Lymphoma After Eradication of Helicobacter Pylori
Completed·Eisai logoEisai·N/A·NCT01264822·108 enrolled
Antibiotic Therapy and Antacids in Patients With Malt Lymphoma of the Stomach
Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00002682·5 enrolled
VELCADE in MALT Lymphoma Pretreated With Prior Systemic Therapy
Completed·IInternational Extranodal Lymphoma Study Group (IELSG)·Phase 2·NCT00210327·33 enrolled
Randomized Trial of Chlorambucil Versus Chlorambucil Plus Rituximab Versus Rituximab in MALT Lymphoma
Completed·IInternational Extranodal Lymphoma Study Group (IELSG)·Phase 3·NCT00210353·454 enrolled
Prospective Study of First-line Antibiotic Therapy for Early-stage Gastric MALT Lymphoma for Treatment Outcome
Completed·National Health Research Institutes, Taiwan·N/A·NCT00327132·47 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)